3 research outputs found

    Π€Π°ΠΊΡ‚ΠΎΡ€ΠΈ Π·Π° Ρ€Π°Π·Π²ΠΎΡ˜ Π½Π° ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ со Ρ‚Π΅ΡˆΠΊΠ° астма

    Get PDF
    РСвСрзибилност Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π°Ρ‚Π° ΠΈ Π±Ρ€ΠΎΠ½Ρ…ΠΈΡ˜Π°Π»Π½Π° хипСррСактивност сС обСлСТја Π½Π° астмата ΠΊΠ°ΠΊΠΎ Π·Π°Π±ΠΎΠ»ΡƒΠ²Π°ΡšΠ΅. Но кај Π΄Π΅Π» ΠΎΠ΄ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ сС Ρ€Π°Π·Π²ΠΈΠ²Π° ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° опструк- Ρ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π° која Π½Π΅ Ρ€Π΅Π°Π³ΠΈΡ€Π° Π½Π° стандардната Ρ‚Π΅Ρ€Π°ΠΏΠΈΡ˜Π°, ΠΈΠΌΠ° ΠΏΠΎΠΈΠ·Ρ€Π°Π·Π΅Π½ ΠΌΠΎΡ€- Π±ΠΈΠ΄ΠΈΡ‚Π΅Ρ‚, присуство Π½Π° ΠΊΠΎΠΌΠΎΡ€Π±ΠΈΠ΄ΠΈΡ‚Π΅Ρ‚ΠΈ ΠΈ лош исход. ΠœΠΎΡ‚ΠΈΠ² ΠΈ Ρ†Π΅Π». Π”Π΅Ρ„ΠΈΠ½ΠΈΡ€Π°ΡšΠ΅ Π½Π° Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΈΡ‚Π΅ ΠΊΠΎΠΈ придонСсуваат ΠΊΠΎΠ½ појава Π½Π° ΠΈΡ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° ΠΈ моТност Π·Π° Π½ΠΈΠ²Π½ΠΎ ΠΌΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€Π°ΡšΠ΅ Π±ΠΈ Π±ΠΈΠ»ΠΎ Π·Π½Π°Ρ‡Π°Ρ˜Π½ΠΎ Π²ΠΎ ΠΏΡ€Π΅Π²Π΅Π½ΠΈΡ€Π°ΡšΠ΅ Π½Π° ΠΌΠΎΡ€Π±ΠΈΠ΄ΠΈΡ‚Π΅Ρ‚ΠΎΡ‚ кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅, ΠΏΠΎΡ€Π°Π΄ΠΈ ΡˆΡ‚ΠΎ сС ΠΎΠ±ΠΈΠ΄ΠΎΠ²ΠΌΠ΅ Π΄Π° Π³ΠΈ ΡƒΡ‚Π²Ρ€Π΄ΠΈΠΌΠ΅ Ρ€ΠΈΠ·ΠΈΠΊ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΈΡ‚Π΅ Π·Π° појава Π½Π° ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π°, ΠΈ Ρ€Π°Π·Π»ΠΈΠΊΠΈΡ‚Π΅ Π²ΠΎ однос Π½Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π°. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΡ˜Π°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ. Π‘ΠΏΡ€ΠΎΠ²Π΅Π΄ΠΎΠ²ΠΌΠ΅ рСтроспСк- Ρ‚ΠΈΠ²Π½Π° ΡΡ‚ΡƒΠ΄ΠΈΡ˜Π° Π²ΠΎ која Π²ΠΊΠ»ΡƒΡ‡ΠΈΠ²ΠΌΠ΅ 70 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π½ΠΈ ΠΎΠ΄ Ρ‚Π΅ΡˆΠΊΠ° астма, ΠΊΠΎΠΈ Π²ΠΎ Ρ‚Π΅ΠΊΠΎΡ‚ Π½Π° 2010 ΠΈ 2011 Π³ΠΎΠ΄ΠΈΠ½Π° сС Π»Π΅ΠΊΡƒΠ²Π°Π»Π΅ амбулантски ΠΈΠ»ΠΈ Π±ΠΎΠ»Π½ΠΈΡ‡ΠΊΠΈ Π½Π° Π˜Π½Ρ‚Π΅Ρ€Π½ΠΎ ΠΎΠ΄Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΠΎ ΠšΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠ° Π±ΠΎΠ»Π½ΠΈΡ†Π° Π¨Ρ‚ΠΈΠΏ. Π˜ΡΠΏΠΈΡ‚Π°Π½ΠΈΡ†ΠΈΡ‚Π΅ Π±Π΅Π° Π½Π° возраст Π½Π°Π΄ 14 Π³ΠΎΠ΄ΠΈΠ½ΠΈ, со Π½Π°Ρ˜ΠΌΠ°Π»ΠΊΡƒ Π΅Π΄Π΅Π½ рСспираторСн симптом: диспнСа, ΠΊΠ°ΡˆΠ»ΠΈΡ†Π°, ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° спутум ΠΈΠ»ΠΈ Π²ΠΈΠ·ΠΈΠ½Π³ ΠΏΠΎΠ΄ΠΎΠ»Π³ΠΎ ΠΎΠ΄ Ρ‚Ρ€ΠΈ мСсСци, сСкојднСвни симптоми ΠΈ чСсти ноќни симптоми, чСсти Π΅Π³Π·Π°Ρ†Π΅Ρ€Π±Π°Ρ†ΠΈΠΈ ΠΈ FEV1 ΠΏΠΎΠΌΠ°Π»ΠΊΡƒ ΠΎΠ΄ 60% ΠΎΠ΄ ΠΏΡ€Π΅Π΄Π²ΠΈΠ΄Π΅Π½Π°Ρ‚Π° врСдност. Π—Π° Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° сС ΡΠΌΠ΅Ρ‚Π°ΡˆΠ΅ Π΄ΠΎΠΊΠΎΠ»ΠΊΡƒ постои ΠΏΠΎΠ΄ΠΎΠ±Ρ€ΡƒΠ²Π°ΡšΠ΅ Π½Π° FEV1 Π½Π°Ρ˜ΠΌΠ°Π»ΠΊΡƒ 12% послС ΠΈΠ½Ρ…Π°Π»Π°Ρ†ΠΈΡ˜Π° Π½Π° Π±Ρ€ΠΎΠ½Ρ…ΠΎΠ΄ΠΈΠ»Π°Ρ‚Π°Ρ‚ΠΎΡ€. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ Π±Π΅Π° ΠΏΠΎΠ΄Π΅Π»Π΅Π½ΠΈ Π²ΠΎ Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΈ, ΠΏΡ€Π²Π° Π³Ρ€ΡƒΠΏΠ° со ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π° ΠΈ FEV1/FVC < 0.7 Π½Π° Π½Π°Ρ˜ΠΌΠ°Π»ΠΊΡƒ Π΄Π²Π΅ послСдоватСлни спиромСтрии, ΠΈ Π²Ρ‚ΠΎΡ€Π° Π³Ρ€ΡƒΠΏΠ° со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° ΠΈ FEV1/FVC > 0.7. Π“ΠΈ Π±Π΅Π»Π΅ΠΆΠ΅Π²ΠΌΠ΅ Π΄ΠΎΠ»ΠΆΠΈΠ½Π°Ρ‚Π° Π½Π° Ρ‚Ρ€Π°Π΅ΡšΠ΅ Π½Π° болСста, возраст Π½Π° Π·Π°Π±ΠΎΠ»ΡƒΠ²Π°ΡšΠ΅, Π±Ρ€ΠΎΡ˜ Π½Π° Π΅Π³Π·Π°Ρ†Π΅Ρ€Π±Π°Ρ†ΠΈΠΈ, присуство Π½Π° риносинузитис, Π°Ρ‚ΠΎΠΏΠΈΡ‡Π΅Π½ статус ΠΈ Ρ€Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ ΠΎΠ΄ лабораториски тСстови. ΠŸΠΎΡ‚ΠΎΠ° Π³ΠΈ спорСдивмС ситС ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΈ ΠΏΠΎΠΌΠ΅Ρ“Ρƒ Π΄Π²Π΅Ρ‚Π΅ испитувани Π³Ρ€ΡƒΠΏΠΈ Π·Π° Π΄Π° ΡƒΡ‚Π²Ρ€Π΄ΠΈΠΌΠ΅ Π·Π½Π°Ρ‡Π°Ρ˜Π½ΠΈ Ρ€Π°Π·Π»ΠΈΠΊΠΈ ΠΏΠΎΠΌΠ΅Ρ“Ρƒ иститС. Π Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚ΠΈ. Од Π²ΠΊΡƒΠΏΠ½ΠΎ 70 испитаници, 36 (51%) ΠΈΠΌΠ°Π° ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π°, Π° 34 (49%) ΠΈΠΌΠ°Π° Ρ€Π΅- Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π°. Π˜ΡΠΏΠΈΡ‚Π°Π½ΠΈΡ†ΠΈΡ‚Π΅ со ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏ-ΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π±Π΅Π° Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»Π½ΠΎ постари (59,7 Π³ΠΎΠ΄ΠΈΠ½ΠΈ) ΠΎΠ΄ ΠΎΠ½ΠΈΠ΅ со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° (48,2 Π³ΠΎΠ΄ΠΈΠ½ΠΈ) ΠΈ ΠΏΠΎΠ²Π΅ΡœΠ΅Ρ‚ΠΎ Π±Π΅Π° ΠΌΠ°ΠΆΠΈ (64%), со ΠΏΠΎΠ΄ΠΎΡ†Π½Π° возраст Π½Π° Π·Π°Π±ΠΎΠ»ΡƒΠ²Π°ΡšΠ΅ (47,5 Π³ΠΎΠ΄ΠΈΠ½ΠΈ) Π²ΠΎ однос Π½Π° испитаницитС со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° (37,7 Π³ΠΎΠ΄ΠΈΠ½ΠΈ) ΠΈ ΠΈΠΌΠ°Π° ΠΏΠΎΠ΄ΠΎΠ»Π³ ΠΏΡƒΡˆΠ°Ρ‡ΠΊΠΈ стаТ (30 pack-years) Π²ΠΎ однос Π½Π° испитаницитС со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° (14 pack-years). Π ΠΈ- носинузитисот ΠΏΠ°ΠΊ бСшС Π·Π½Π°Ρ‡Π°Ρ˜Π½ΠΎ почСст кај испитаницитС со Ρ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° (63%) ΠΎΡ‚ΠΊΠΎΠ»ΠΊΡƒ кај испитаницитС со ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° (47%). НС ΡƒΡ‚Π²Ρ€Π΄ΠΈΠ²ΠΌΠ΅ Π·Π½Π°Ρ‡Π°Ρ˜Π½ΠΈ Ρ€Π°Π·Π»ΠΈΠΊΠΈ Π²ΠΎ однос Π½Π° Π±Ρ€ΠΎΡ˜ΠΎΡ‚ Π½Π° Π΅Π³Π·Π°Ρ†Π΅Ρ€Π±Π°Ρ†ΠΈΠΈ, Π‘ΠœΠ˜, Π°Ρ‚ΠΎΠΏΠΈΡ‡Π½ΠΈΠΎΡ‚ статус, Π½ΠΈΡ‚Ρƒ Π·Π½Π°Ρ‡Π°Ρ˜Π½ΠΈ Π³Ρ€ΡƒΠΏΠ½ΠΈ Ρ€Π°Π·Π»ΠΈΠΊΠΈ Π²ΠΎ Π»Π°- бораторискитС Π°Π½Π°Π»ΠΈΠ·ΠΈ (Π˜Π³Π•, ЦРП, ΠΊΡ€Π²Π½Π° сли- ΠΊΠ°, Π»Π΅ΡƒΠΊΠΎΡ†ΠΈΡ‚Π½Π° Ρ„ΠΎΡ€ΠΌΡƒΠ»Π°). Како Π½Π°Ρ˜Π·Π½Π°Ρ‡Π°Π΅Π½ нСзависСн Ρ€ΠΈΠ·ΠΈΠΊ Ρ„Π°ΠΊΡ‚ΠΎΡ€ Π·Π° ирСвСрзибилност Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π°Ρ‚Π° сС ΠΏΠΎΠΊΠ°ΠΆΠ° ΠΏΡƒΡˆΠ΅ΡšΠ΅Ρ‚ΠΎ, исто ΠΈ Π΄ΠΎΠ»Π³ΠΎΡ‚Ρ€Π°Ρ˜Π½Π° болСст Π½Π°Π΄ 15 Π³ΠΎΠ΄ΠΈΠ½ΠΈ ΠΈ отсуство Π½Π° риносинузитис. Π—Π°ΠΊΠ»ΡƒΡ‡ΠΎΠΊ. Π£Ρ‚Π²Ρ€Π΄ΠΈΠ²ΠΌΠ΅ Π΄Π΅ΠΊΠ° ΠΏΠΎΠ΄ΠΎΠ»Π³ΠΎ Ρ‚Ρ€Π°Π΅ΡšΠ΅ Π½Π° болСста Π±Π΅Π· ΠΏΡ€ΠΎΠΏΡ€Π°Ρ‚Π΅Π½ риносинузитис ΠΈ ΠΏΡƒΡˆΠ΅ΡšΠ΅ сС Ρ€ΠΈΠ·ΠΈΠΊ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΈ Π·Π° Ρ€Π°Π·Π²ΠΎΡ˜ Π½Π° ΠΈΡ€Π΅Π²Π΅Ρ€Π·ΠΈΠ±ΠΈΠ»Π½Π° ΠΏΠ΅Ρ€ΠΌΠ°Π½Π΅Π½Ρ‚Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π° Π½Π° Π΄ΠΈΡˆΠ½ΠΈΡ‚Π΅ ΠΏΠ°Ρ‚ΠΈΡˆΡ‚Π° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ со Ρ‚Π΅ΡˆΠΊΠ° астма ΠΈ ΠΏΡ€Π΅ΠΊΠΈΠ½ Π½Π° ΠΏΡƒΡˆΠ΅ΡšΠ΅Ρ‚ΠΎ ΠΌΠΎΠΆΠ΅ Π΄Π° ΠΈΠΌΠ° Π·Π½Π°Ρ‡Π°Π΅Π½ Π±Π΅Π½Π΅Ρ„ΠΈΡ‚ Π·Π° ΠΎΠ²ΠΈΠ΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ. Π’Ρ€Π΅Π±Π° Π΄Π° сС Ρ€Π°Π·- Π±Π΅Ρ€Π΅ хСтСрогСноста Π½Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ со Ρ‚Π΅ΡˆΠΊΠ° астма, ΠΈ со ΠΏΠΎΠ½Π°Ρ‚Π°ΠΌΠΎΡˆΠ½ΠΈ ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ° ΠΊΠΎΠΈ Π±ΠΈ Π³ΠΈ Ρ€Π°Π·Ρ˜Π°ΡΠ½ΠΈΠ»Π΅ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠΈΡ‚Π΅ Π½Π° Π½Π°ΡΡ‚Π°Π½ΡƒΠ²Π°ΡšΠ΅ Π½Π° Ρ€Π°Π·Π½ΠΈΡ‚Π΅ субтипови Π±ΠΈ ΠΌΠΎΠΆΠ΅Π»ΠΎ Π΄Π° сС ΠΏΡ€Π΅Π²Π΅Π½ΠΈΡ€Π° Π½Π°ΠΏΡ€Π΅Π΄ΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ Π½Π° ΠΎΠΏΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡ˜Π°Ρ‚Π° ΠΈ Π½Π΅Ρ˜Π·ΠΈΠ½ΠΈΡ‚Π΅ послСдици

    Thromboembolism after partus praeteporarius spontaneus

    Get PDF
    Thromboembolism after partus praeteporarius spontaneus is not unusual but need multidisciplinary treatment

    Newly diagnosed multiple myeloma after Covid-19 infection

    Get PDF
    Introduction:Myltiple myeloma is a malignant proliferation of plasma cells producing paraprotein, the second most common hematologic malignancy. Myltiple myeloma can present in different ways for example hypercalcemia, hyperviscosity, renal failure and bone pains. The primary cause of morbidity and mortality in patients with MM is an infection. Covid 19 is an infection disease caused by SARS-COV2 who has became a global pandemic and serious health problem. Objectives:70 years old female who has a history of fatigue, anemic syndrome, lost of weight 5kg in past 3 mounts, renal failure and also hospitalization of two weeks at department for infective disease (Covid-19 positive) was hospitalized in our department. From comorbidities she has HTA and hysterectomy done at aged of 50. On examination was cachectic with dyspnea and sinus tachycardia. Materials and methods: Laboratory findings=high sedimendation (130), normochromic anemia (hgb=79, rbc=2.57, mcv=83.6), hyperuricemia (146), negative tumor markers (cea, ca 15-3, ca 19-9, ca 125), elevated urea (16) and creatinin (169.5), +1 of protein on urinanalysis, negative markers for hepatitis B and C. Gastroscopy - Gastritis chronica. Erosiones chr.mucosae ventriculi. CT scan of abdomen and pelvis = non significant ascites in the pelvis. Diffuse small osteolitic lesions are seen on skeletal window. Results: This patients was transferred to Clinic of Hematology the diagnose was confirmed (Myeloma myltiplex IgG type), Sternal punction - infiltration with plasma cells 80%, chemotherapy was started and because of syndrome of hyperviscosity (total proteins 154, IgG 107) were done also two plasmapheresis. Conclusion:The case confirmed the necessity of preventive measures worldwide to protect vulnerable patients from SARS-COV2 infection and especially MM-patients that have not been diagnosed on time or have died during pandemic. Keywords:MM (myltiple myeloma), Sars Cov
    corecore